It depends on the standard you follow. As of September 2026, Haemonetics Corporation (HAE) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 22.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.60% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 22.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.14% / 33% · Receivables / Mkt Cap (36m) 4.44% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 22.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.14% / 33.33% · Receivables / Mkt Cap (24m) 4.44% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 49.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 11.3% / 33.33% · Receivables / Avg Assets (4Q) 8.83% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 46.6% / 33.33% · (Cash+ST Inv) / Total Assets 10.8% / 33.33% · (Cash+Recv) / Total Assets 20.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Haemonetics Corporation (HAE) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Haemonetics Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Haemonetics Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 26, 2026 (Q2 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Haemonetics Corporation (NYSE: HAE) is a Healthcare company (Medical - Devices) with a market capitalization of $5.5B. The Maz Rating grades it against the other companies in its sector.
Haemonetics Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $120.92, Haemonetics Corporation trades at 53.2x trailing earnings, 4.0x sales and 6.1x book value, with an EV/EBITDA of 23.0. Over the last twelve months it generated about $1.4B of revenue and $104M of net income. It runs a gross margin of 58.8%, an operating margin of 18.3% and a net margin of 7.5%. It shows return on equity of 12.1%, return on invested capital of 8.8% and a free cash flow yield of 5.5%. On the balance sheet: a debt-to-equity ratio of 1.25 and a current ratio of 2.84. Over the past 52 weeks the share price ranged from $51.00 to $132.00, with a beta of 0.54.
Haemonetics Corporation does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 12 Buy and 9 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.